Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors.


Journal

Journal of the American Chemical Society
ISSN: 1520-5126
Titre abrégé: J Am Chem Soc
Pays: United States
ID NLM: 7503056

Informations de publication

Date de publication:
10 06 2020
Historique:
pubmed: 16 5 2020
medline: 14 4 2021
entrez: 16 5 2020
Statut: ppublish

Résumé

With a resurgence in interest in covalent drugs, there is a need to identify new moieties capable of cysteine bond formation that are differentiated from commonly employed systems such as acrylamide. Herein, we report on the discovery of new alkynyl benzoxazine and dihydroquinazoline moieties capable of covalent reaction with cysteine. Their utility as alternative electrophilic warheads for chemical biological probes and drug molecules is demonstrated through site-selective protein modification and incorporation into kinase drug scaffolds. A potent covalent inhibitor of JAK3 kinase was identified with superior selectivity across the kinome and improvements in

Identifiants

pubmed: 32412754
doi: 10.1021/jacs.9b13391
doi:

Substances chimiques

Benzoxazines 0
Protein Kinase Inhibitors 0
Quinazolines 0
JAK3 protein, human EC 2.7.10.2
Janus Kinase 3 EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10358-10372

Auteurs

Kirsten McAulay (K)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

Emily A Hoyt (EA)

Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.

Morgan Thomas (M)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

Marianne Schimpl (M)

Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Cambridge CB4 0WG, U.K.

Michael S Bodnarchuk (MS)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

Hilary J Lewis (HJ)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

Derek Barratt (D)

Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Cambridge CB4 0WG, U.K.

Deepa Bhavsar (D)

Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.

David M Robinson (DM)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

Michael J Deery (MJ)

Cambridge Centre for Proteomics, Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, U.K.

Derek J Ogg (DJ)

Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Cambridge CB4 0WG, U.K.

Gonçalo J L Bernardes (GJL)

Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
Instituto de Medicina Molecular, Faculdade de Medicina de Universidad de Lisboa, Avenida Prof. Egas Moniz, 1649-028 Lisboa, Portugal.

Richard A Ward (RA)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

Michael J Waring (MJ)

Northern Institute for Cancer Research, Chemistry, School of Natural and Environmental Sciences, Newcastle University, Bedson Building, Newcastle upon Tyne NE1 7RU, U.K.

Jason G Kettle (JG)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH